MEWO
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
MEWO |
Humane Haut Melanom Zell-Linie |
300285 |
cryovial |
265,00 |
MEWO |
Humane Haut Melanom Zell-Linie |
330285 |
vital |
335,00 |
| Designation: | MEWO |
| Depositor: | CLS |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Tissue: | melanoma, malignant; skin |
| Morphology: | stellate |
| Growth Properties: | adherent |
| Description: | Product melanin, derived from a human melanoma by Prof.C.Grose (1978). The cells support growth of varicella-zoster virus (VZV) isolates at 36°C although growth is optimal at 32°C. |
| Culture Medium: | Minimum essential medium (Eagle) in Earle's BSS supplemented with 2 mM L-glutamine, 1% nonessential amino acids, 1 mM sodium pyruvate and 10% fetal bovine serum. Alternatively, DMEM:F12 (1:1 mixture) supplemented with 2 mM L-glutamine and 10% fetal bovine serum may be used. |
| Subculturing: | Remove medium, add fresh 0.025% trypsin solution for 1 minute, remove trypsin and let the culture sit at room temperature for 5 to 10 minutes. Add fresh medium, aspirate and dispense into new flasks. Subculture every 6 to 8 days. |
| Split Ratio: | A ratio of 1:3 to 1:6 is recommended |
| Fluid Renewal: | 2 to 3 times per week |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice; forms malignant melanoma |
| DNA Profile (STR): | Amelogenin: X / Y CSF1PO: 12/12 D13S317: 8/9 D16S539: 10/12 D5S818: 12/13 D7S820: 10/12 THO1: 7/9 TPOX: 8/10 vWA: 15/15 D3S1358: 17/17 D21S11: 30/32.2 D18S51: 14/17 Penta E: 5/5 Penta D: 10/10 D8S1179: 13/15 FGA: 22/22 CLS ∙ Cell Lines Service, 2009. |
| Applications: | Virus studies |
References: Puche JG et al. Complement-dependent serum cytotoxicity of cancer patients studied by 51Cr release assay on human cancer lines. Tumori 63: 97-108, 1977. Kadish AS et al. Interfreon as a mediator of human lymphocyte supression. J Exp Med 151: 637-50, 1980. Denkert C et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61: 303-8, 2001. Christmann M et al. Acquired resistance of melanoma cells to the anti-neoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 92:123-9, 2001. Schirrmacher V et al. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol 18: 945-52, 2001. Chen H et al. The role of phosphoinositide-3-kinase in the soring and transport of newly synthesized tyrosinase-related protein-1 (TRP-1). J Investig Dermatol Symp Proc 6: 105-14, 2001. De Nardo C et al. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells. J Cell Physiol 190: 200-6, 2002. Shannan B et al. Clusterin /CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res 26: 2707-16, 2006. Munshi A et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5: 1967-74, 2006. | |
